fluralaner / moxidectin
Bravecto Plus is a veterinary medicine used in cats to treat mixed infestations with both ticks or fleas and ear mites and/or worms that live inside the body. The medicine can be used:
- to treat tick infestations
- to treat flea infestations. It can also be used as part of a treatment for flea allergy dermatitis (an allergic reaction to flea bites)
- to treat ear mite infestations
- to treat roundworms and hookworms in the gut
- to prevent heartworm disease
Bravecto Plus must only be used when there is a need to treat ticks or fleas and one or more of the parasites listed above. Bravecto Plus contains the active substances fluralaner and moxidectin.
Bravecto Plus : EPAR - Medicine overview (PDF/148.43 KB)
First published: 07/06/2018
Last updated: 12/02/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
Intervet International B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Wim de Körverstraat 35
03/12/2021 Bravecto Plus - EMEA/V/C/004440 - IB/0022
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antiparasitic products, insecticides and repellents
For cats with, or at risk from, mixed parasitic infestations by ticks or fleas and ear mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas and one or more of the other target parasites is indicated at the same time.
For the treatment of tick and flea infestations in cats providing immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
For the treatment of infestations with ear mites (Otodectes cynotis).
For the treatment of infections with intestinal roundworm (4th stage larvae, immature adults and adults of Toxocara cati) and hookworm (4th stage larvae, immature adults and adults of Ancylostoma tubaeforme).
When administered repeatedly at a 12-week interval, the product continuously prevents heartworm disease caused by Dirofilaria immitis
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 5-7 October 202108/10/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 July 202116/07/2021